Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy

被引:49
|
作者
Sun, Yating [1 ]
Zhao, Yarong [1 ]
Teng, Shanshan [1 ]
Hao, Fei [1 ]
Zhang, Huan [1 ]
Meng, Fanchao [1 ]
Zhao, Xiuting [1 ]
Zheng, Xiaolong [1 ]
Bi, Ye [1 ]
Yao, Yicheng [2 ]
Lee, Robert J. [1 ,3 ]
Teng, Lesheng [1 ]
机构
[1] Jilin Univ, Sch Life Sci, 2699 Qianjin Ave, Changchun, Jilin, Peoples R China
[2] Acalanes High Sch, Lafayette, CA USA
[3] Ohio State Univ, Coll Pharm, Div Pharmaceut, 500 W 12Th Ave, Columbus, OH 43210 USA
来源
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
folic acid; human serum albumin; nanoparticles; cabazitaxel; folic acid receptor; CONJUGATED NANOPARTICLES; FOLATE; DOCETAXEL; RESISTANT; DELIVERY; AGENT;
D O I
10.2147/IJN.S181296
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Background: We previously developed cabazitaxel (CTX)-loaded human serum albumin nanoparticles (NPs-CTX) via a self-assembly method, and these NPs showed efficacy in prostate cancer therapy. Many studies have shown that the levels of folic acid (FA) receptor on the surface of various tumor cells are high. Therefore, FA-modified NPs-CTX may have enhanced antitumor effects compared with unmodified NPs-CTX. Methods: NPs-CTX were first prepared via self-assembly, and FA was conjugated on the surface of NPs-CTX through the -NH2 groups of the NPs to produce FA-NPs-CTX. The FA-NPs-CTX were evaluated in tumor cells with high FA receptor (FR) expression in vitro and in vivo. Results: Both NPs-CTX and FA-NPs-CTX exhibited good stability and morphology. Drug release from the NPs was not affected by FA conjugation. Compared with CTX dissolved in a mixture of Tween 80 and 13% ethanol (w/w) at a ratio of 1: 4 (v/v) (Tween-CTX), the two nanoformulations had lower lytic activity against normal red blood cells. However, FA-NPs-CTX showed greater inhibition of tumor cells with overexpressed FR, compared with NPs-CTX, in the cytotoxicity experiments. Moreover, the cellular uptake of FA-NPs-CTX was enhanced through FR-mediated endocytosis in HeLa cells in vitro and HeLa xenograft tumors in vivo. Although Tween-CTX exhibited tumor growth inhibition similar to FA-NPs-CTX in vivo, this inhibition also caused adverse side effects; the median lethal dose (LD50) of Tween-CTX to mice was 5.68 mg/kg, while FA-NPs-CTX-treated mice survived at doses exceeding 400 mg/kg. Conclusion: The results showed that FA-NPs-CTX caused inhibition of tumor growth in a manner similar to that of Tween-CTX; however, the safety and tolerability of CTX were greatly improved by FA conjugation compared with those of Tween-CTX. In summary, FA-NPs-CTX have great potential in CTX delivery, and this formulation is a promising candidate for the treatment of cancers with high FR levels.
引用
收藏
页码:135 / 148
页数:14
相关论文
共 50 条
  • [31] Folic acid-modified ginsenoside Rg5-loaded bovine serum albumin nanoparticles for targeted cancer therapy in vitro and in vivo
    Dong, Yanan
    Fu, Rongzhan
    Yang, Jing
    Ma, Pei
    Liang, Lihua
    Mi, Yu
    Fan, Daidi
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2019, 14 : 6971 - 6988
  • [32] A pH/GSH Dual-Responsive, Folic Acid Targeted Drug Delivery System Based on Bovine Serum Albumin Nanoparticles for Cancer Therapy
    Xiong, Bei
    Liu, Huimin
    Yi, Mengqi
    Li, Yuyang
    Huang, Yunhan
    Guo, Wei
    Lin, Yangxin
    Liu, Ping
    Lu, Bo
    PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION, 2024, 41 (06)
  • [33] Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways
    Kawakami, M
    Kawakami, K
    Puri, RK
    INTERNATIONAL JOURNAL OF CANCER, 2003, 103 (01) : 45 - 52
  • [34] Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy
    Haller, Stephanie
    Reber, Josefine
    Brandt, Simone
    Bernhardt, Peter
    Groehn, Viola
    Schibli, Roger
    Mueller, Cristina
    NUCLEAR MEDICINE AND BIOLOGY, 2015, 42 (10) : 770 - 779
  • [35] Bovine serum albumin framed activatable NIR AIE photosensitizer for targeted tumor therapy
    Wu, Kun
    Liu, Jiawei
    Zhang, Xinmin
    Chao, Zhicong
    Fang, Yanyun
    Zhu, Yu
    Liu, Yuan
    Zhang, Xiaobo
    Wang, Qi
    Ju, Huangxian
    Liu, Ying
    BIOMATERIALS, 2025, 315
  • [36] Synthesis and biological evaluation of a novel cancer treatment based on folic acid receptor-targeted, β-cyciodextrin-based drug complexes
    Yin, Juan-Juan
    Zhou, Shufeng
    CANCER RESEARCH, 2013, 73 (08)
  • [37] A Novel Folic Acid Receptor-Targeted Drug Delivery System Based on Curcumin-Loaded β-Cyclodextrin Nanoparticles for Cancer Treatment
    Hong, Weiyong
    Guo, Fangyuan
    Yu, Nan
    Ying, Sanjun
    Lou, Bang
    Wu, Jiangqing
    Gao, Ying
    Ji, Xugang
    Wang, Haiying
    Li, Aiqin
    Wang, Guoping
    Yang, Gensheng
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2843 - 2855
  • [38] MEDI 54-Design and synthesis of a folate receptor-targeted chemotherapeutics: Folic acid conjugate of desacetylvinblastine hydrazide (EC 145)
    Vlahov, Iontcho R.
    Santhapuram, Hari Krishna R.
    Kleindl, Paul J.
    Howard, Stephen J.
    Stanford, Katheryn M.
    Leamon, Christopher P.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [39] Formulation and characterization of folate receptor-targeted PEGylated liposome encapsulating bioactive compounds from Kappaphycus alvarezii for cancer therapy
    Suraj Baskararaj
    Theivendren Panneerselvam
    Saravanan Govindaraj
    Sankarganesh Arunachalam
    Pavadai Parasuraman
    Sureshbabu Ram Kumar Pandian
    Murugesan Sankaranarayanan
    Uma Priya Mohan
    Ponnusamy Palanisamy
    Vigneshwaran Ravishankar
    Selvaraj Kunjiappan
    3 Biotech, 2020, 10
  • [40] Formulation and characterization of folate receptor-targeted PEGylated liposome encapsulating bioactive compounds from Kappaphycus alvarezii for cancer therapy
    Baskararaj, Suraj
    Panneerselvam, Theivendren
    Govindaraj, Saravanan
    Arunachalam, Sankarganesh
    Parasuraman, Pavadai
    Pandian, Sureshbabu Ram Kumar
    Sankaranarayanan, Murugesan
    Mohan, Uma Priya
    Palanisamy, Ponnusamy
    Ravishankar, Vigneshwaran
    Kunjiappan, Selvaraj
    3 BIOTECH, 2020, 10 (03)